Medical Marijuana, Inc (MJNA), the first publicly traded cannabis company in the United States, announced that its subsidiary HempMeds Mexico has revealed the positive results of a recent study conducted by renowned Mexican physician Dr Saul Garza Morales, on the effects of the Real Scientific Hemp Oil-X (RSHO-X) product in treating children with severe epilepsy.

The study, conducted by Mexican pediatric neurologist Dr Garza, included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four.

Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 7 reported a complete elimination of all seizures over a 4-month period, with zero reported side effects.

"7 children reported a complete elimination of all seizures over a 4-month period, with zero reported side effects"

"The results of this study are very exciting as they show the best results of any product/medication ever recorded regarding the reduction of seizures in Lennox-Gastaut Syndrome patients, with 17% of patients in the study experiencing 100% relief from their seizures," said CEO of Medical Marijuana, Inc., Dr Stuart Titus.

"Studies that prove the therapeutic benefits of CBD are vital, as they will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe. This is such encouraging news that children with such a severe form of epilepsy now have an option for relief as opposed to a prior bleak diagnosis that offered no signs of beneficial treatment, once the epilepsy moves to the refractory (drug resistant) phase.

Register as Visitor to CPhI China 2019!

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.